AR077018A1 - Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel. - Google Patents
Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel.Info
- Publication number
- AR077018A1 AR077018A1 ARP100102008A ARP100102008A AR077018A1 AR 077018 A1 AR077018 A1 AR 077018A1 AR P100102008 A ARP100102008 A AR P100102008A AR P100102008 A ARP100102008 A AR P100102008A AR 077018 A1 AR077018 A1 AR 077018A1
- Authority
- AR
- Argentina
- Prior art keywords
- clopidogrel
- layer
- sch
- bisulfate
- tablet
- Prior art date
Links
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 title abstract 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title abstract 4
- 229960003009 clopidogrel Drugs 0.000 title abstract 4
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 abstract 3
- 229960005044 vorapaxar Drugs 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta solicitud ofrece un compuesto farmacéutico el cual incluye a) un compuesto de la formula SCH 530348 o la sal del bisulfato de aquel; b) clopidogrel; y c) celulosa microcristalina silificada. Reivindicacion 6: El comprimido de doble capa de la reivindicacion 5 incluye una primera capa que contiene bisulfato SCH 530348 y una segunda capa que contiene clopidogrel. Reivindicacion 9: Este comprimido de doble capa de la reivindicacion 6 en donde la cantidad del bisulfato SCH 530348 en dicha primera capa es de aproximadamente 2,5 mg y la cantidad de clopidogrel en la segunda capa es de aproximadamente 75 mg. Reivindicacion 10: Un método para tratar un trastorno cardiovascular que consiste en administrar a un mamífero que necesite dicho tratamiento una cantidad efectiva del compuesto farmacéutico de la reivindicacion 1. Reivindicacion 12: El método de acuerdo con la reivindicacion 11 en donde dicho trastorno cardiovascular se selecciona de un grupo que consiste de un síndrome coronario agudo, enfermedad arterial periférica, trombosis, ateroesclerosis, reestenosis, hipertension, angina de pecho, arritmia, insuficiencia cardíaca, infarto del miocardio, glomerulonefritis, trombosis cerebral, derrame tromboembolico e isquemia cerebral. Reivindicacion 13: Un método para prevenir un trastorno asociado con la cirugía de bypass de la arteria coronaria que consiste en administrar a un sujeto sometido a dicha cirugía un comprimido de acuerdo con cualquier reivindicacion 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18506809P | 2009-06-08 | 2009-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077018A1 true AR077018A1 (es) | 2011-07-27 |
Family
ID=43309422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102008A AR077018A1 (es) | 2009-06-08 | 2010-06-08 | Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120141586A1 (es) |
| EP (1) | EP2440191A2 (es) |
| JP (1) | JP2012529431A (es) |
| AR (1) | AR077018A1 (es) |
| AU (1) | AU2010259003A1 (es) |
| CA (1) | CA2764172A1 (es) |
| MX (1) | MX2011013091A (es) |
| TW (1) | TW201110968A (es) |
| WO (1) | WO2010144339A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058550B (zh) * | 2010-12-30 | 2016-04-27 | 江苏亚邦强生药业有限公司 | 硫酸氢氯吡格雷片及其制备方法 |
| US20140378502A1 (en) * | 2011-05-12 | 2014-12-25 | UNIVERSITé LAVAL | Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections |
| JP2016204260A (ja) * | 2013-10-04 | 2016-12-08 | 日本曹達株式会社 | 錠剤の製造方法 |
| CN104083333B (zh) * | 2014-07-09 | 2017-02-15 | 乐普药业股份有限公司 | 硫酸氢氯吡格雷片及其制备方法 |
| CN108078942B (zh) * | 2018-02-01 | 2019-07-19 | 海南天煌制药有限公司 | 一种硫酸氢氯吡格雷片剂及其制备方法 |
| CN116568332A (zh) * | 2020-12-03 | 2023-08-08 | 德尔塔4有限公司 | 氯吡格雷用于治疗局灶性节段性肾小球硬化（fsgs） |
| FR3134314A1 (fr) * | 2022-04-08 | 2023-10-13 | Cvasthera | Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales |
| CN115212180B (zh) * | 2022-09-03 | 2024-05-10 | 深圳市信宜特科技有限公司 | 一种阿司匹林和硫酸氢氯吡格雷的复方制剂及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| MXPA02012447A (es) | 2000-06-15 | 2003-04-25 | Schering Corp | Antagonistas receptores de trombina. |
| AR036832A1 (es) | 2001-10-18 | 2004-10-06 | Schering Corp | Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos |
| US20030206978A1 (en) * | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| EA012329B1 (ru) * | 2002-01-16 | 2009-08-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Способ получения практически аморфного телмисартана |
| PT1495018E (pt) | 2002-04-16 | 2008-02-19 | Schering Corp | Antagonistas tricíclicos de receptores de trombina |
| DE10317816A1 (de) | 2003-04-16 | 2004-11-04 | Claas Selbstfahrende Erntemaschinen Gmbh | Feldhäcksler mit positionierbarer Fahrerkabine |
| WO2006044548A2 (en) | 2004-10-14 | 2006-04-27 | Dr. Reddy's Laboratories Ltd. | Clopidogrel compositions |
| JP2009521472A (ja) | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
| EP2007362B1 (en) * | 2006-04-04 | 2018-09-05 | KG Acquisition LLC | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
| US20070238674A1 (en) * | 2006-04-06 | 2007-10-11 | Veltri Enrico P | Tra combination therapies |
| PE20080183A1 (es) * | 2006-04-06 | 2008-03-10 | Schering Corp | Terapias de combinacion de tra |
| EP2037909A2 (en) | 2006-06-30 | 2009-03-25 | Schering Corporation | Solid dose formulations of a thrombin receptor antagonist |
| TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| TWI343262B (en) | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| EP2134344A1 (en) | 2007-03-23 | 2009-12-23 | Schering Corporation | Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist |
-
2010
- 2010-06-07 CA CA2764172A patent/CA2764172A1/en not_active Abandoned
- 2010-06-07 EP EP10724639A patent/EP2440191A2/en not_active Withdrawn
- 2010-06-07 AU AU2010259003A patent/AU2010259003A1/en not_active Abandoned
- 2010-06-07 JP JP2012514219A patent/JP2012529431A/ja not_active Withdrawn
- 2010-06-07 US US13/376,633 patent/US20120141586A1/en not_active Abandoned
- 2010-06-07 MX MX2011013091A patent/MX2011013091A/es not_active Application Discontinuation
- 2010-06-07 WO PCT/US2010/037581 patent/WO2010144339A2/en not_active Ceased
- 2010-06-08 AR ARP100102008A patent/AR077018A1/es not_active Application Discontinuation
- 2010-06-08 TW TW099118598A patent/TW201110968A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011013091A (es) | 2012-01-12 |
| TW201110968A (en) | 2011-04-01 |
| JP2012529431A (ja) | 2012-11-22 |
| WO2010144339A3 (en) | 2011-05-12 |
| AU2010259003A1 (en) | 2011-11-10 |
| US20120141586A1 (en) | 2012-06-07 |
| EP2440191A2 (en) | 2012-04-18 |
| WO2010144339A2 (en) | 2010-12-16 |
| CA2764172A1 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077018A1 (es) | Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel. | |
| JP2017002083A5 (es) | ||
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| CO6430463A2 (es) | Activadores de guanilato ciclasa solubles | |
| PE20160180A1 (es) | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos. | |
| UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
| Clappers et al. | Antiplatelet treatment for coronary heart disease | |
| Moroni et al. | Relief of ischemia in ischemic cardiomyopathy | |
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| PH12016501129B1 (en) | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | |
| RU2017124150A (ru) | Производное дигидроиндолизинона | |
| BR112017011124A2 (pt) | 1-[2-(aminometil)benzil]-2-tioxo-1,2,3,5-tetraidro-4h-pirrolo[3,2-d]pirimidin-4-ona como inibidor da mieloperoxidase | |
| Paikin et al. | Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials | |
| AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina | |
| AR105752A1 (es) | Métodos para el tratamiento de enfermedades cardiovasculares | |
| MX390718B (es) | Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo. | |
| Manolis et al. | Combined antiplatelet therapy: still a sweeping combination in cardiology | |
| Yoshida et al. | A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease | |
| AR094018A1 (es) | Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos | |
| Steffel et al. | Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| RU2014145827A (ru) | Композиция, включающая амлодипин и лозартан, имеющая улучшенную стабильность | |
| AR075880A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |